

ASX Announcement



Medibio Limited – 14 June 2022

Non-Executive Director Moves to the Growth and Advocacy Advisory Board

Melbourne, Australia and Minneapolis, USA – 14 June 2022: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF) advises that Mr Peter Carlisle has tendered his resignation from his position as Non-Executive Director and Lead Independent Director of the Company, effective on 10 June 2022, in order to focus his time and efforts on the activities of the Growth and Advocacy Advisory Board.

Peter has made a considerable contribution to the Company over many years, and we are pleased that he will continue to contribute as Chairman of the Company's Growth and Advocacy Board. Given the Company is moving into a critical time in the Company's development, Peter's expertise in directing the Growth and Advocacy Advisory Board will be significant.

The Company would like to extend its sincere appreciation to Peter for contribution to the Company over his tenure as a Non-Executive Director.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Investor Enquiries:

Medibio Investor Relations

investors@medibio.com.au

+61 3 9692 7222